サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1526240

ドキソルビシンの世界市場

Doxorubicin

出版日
ページ情報
英文 288 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
ドキソルビシンの世界市場
出版日: 2024年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 288 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ドキソルビシンの世界市場は2030年までに17億米ドルに達する見込み

2023年に11億米ドルと推定されるドキソルビシンの世界市場は、分析期間2023-2030年にCAGR 5.8%で成長し、2030年には17億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである乳がんアプリケーションは、CAGR 5.6%を記録し、分析期間終了時には3億7,410万米ドルに達すると予測されます。肺がんアプリケーション分野の成長率は、分析期間中CAGR 7.4%と推定されます。

米国市場は4億6,880万米ドルと推定、中国はCAGR 8.1%で成長すると予測

米国のドキソルビシン市場は、2023年に4億6,880万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 8.1%で推移し、2030年には1億4,500万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.4%と5.8%と予測されています。欧州では、ドイツがCAGR 4.7%で成長すると予測されています。

世界のドキソルビシン市場- 主要動向と促進要因まとめ

ドキソルビシンは、乳がん、膀胱がん、カポジ肉腫、リンパ腫、急性リンパ芽球性白血病など、さまざまながんの治療に一般的に使用される強力な化学療法薬です。1960年代に発見されたドキソルビシンはアントラサイクリン系薬剤のクラス別であり、DNA鎖をインターカレートし、トポイソメラーゼIIという酵素を阻害することにより作用します。この作用により、がん細胞の複製を阻止し、死滅に導く。ドキソルビシンは通常静脈内投与され、その特徴的な赤い色で知られ、その強力な効果と重大な副作用プロファイルから「赤い悪魔」というニックネームがついています。その有効性にもかかわらず、ドキソルビシンの使用はその心毒性によって制限されており、注意深く監視・管理されなければ、不可逆的な心臓障害を引き起こす可能性があります。

ドキソルビシンの製剤とデリバリー方法は、その治療指数を高め、毒性の副作用を軽減することを目的とし、大きな進歩を遂げました。この分野での大きなブレークスルーのひとつは、リポソームドキソルビシンの開発であり、リポソームに薬剤を封入することで、健常組織を温存しながら腫瘍細胞により的を絞ったデリバリーを可能にしました。この改良により、心毒性やその他の全身的副作用が軽減され、患者にとってより忍容性の高い治療が可能になることが示されています。さらに、現在進行中の調査では、ドキソルビシンの特異性と有効性をさらに向上させるために、ナノ粒子やその他の新規ドラッグデリバリーシステムの使用が検討されています。プレシジョン・メディシンの進歩により、副作用を最小限に抑えながら治療効果を最大化することを目的とした、個々の患者プロファイルに基づいた個別化投与レジメンへの道も開かれつつあります。

ドキソルビシン市場の成長はいくつかの要因によってもたらされます。世界のがん罹患率の増加は、より多くの患者が効果的な化学療法の選択肢を必要としていることから、重要な促進要因となっています。リポソーム製剤やナノ粒子などのドラッグデリバリー技術の進歩は、ドキソルビシンの有効性と安全性プロファイルを向上させ、その普及を後押ししています。さらに、プレシジョン・メディシン（精密医療）分野の拡大は、よりテーラーメイドな治療レジメンの開発をサポートし、併用療法におけるドキソルビシンの使用を増加させる可能性があります。製薬会社もまた、ドキソルビシンを含む新しい適応症や併用療法を探求するための研究開発に多額の投資を行っています。さらに、新興市場におけるヘルスケアインフラの改善とがん治療へのアクセスの向上が、効果的な化学療法剤の需要を押し上げています。これらの要因は、技術の進歩、がん罹患率の上昇、継続的な研究努力によって、ドキソルビシン市場がダイナミックで進化していることを裏付けています。

調査対象企業の例（全59件）

  • Merck KGaA
  • Glenmark Pharmaceuticals Ltd.
  • Fresenius Kabi AG
  • Fresenius SE & Co. KGaA
  • Natco Pharma Limited
  • Meiji Holdings Co., Ltd.
  • Celsion Corporation
  • Health Biotech Ltd.
  • MicroBiopharm Japan Co., Ltd.
  • Accord Healthcare Ltd.
  • Olon S.p.A.
  • Seqens SAS
  • Biovencer Healthcare Private Limited
  • Avacta Group
  • CSPC Pharmaceutical Group Limited

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 世界市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • 市場分析
  • カナダ
  • 日本
  • 中国
  • 欧州
  • 市場分析
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • 市場分析
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP21662

Global Doxorubicin Market to Reach US$1.7 Billion by 2030

The global market for Doxorubicin estimated at US$1.1 Billion in the year 2023, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2023-2030. Breast Cancer Application, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$374.1 Million by the end of the analysis period. Growth in the Lung Cancer Application segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$468.8 Million While China is Forecast to Grow at 8.1% CAGR

The Doxorubicin market in the U.S. is estimated at US$468.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$145.0 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Doxorubicin Market - Key Trends & Drivers Summarized

Doxorubicin is a potent chemotherapy drug commonly used to treat various types of cancer, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphoblastic leukemia. Discovered in the 1960s, doxorubicin belongs to the anthracycline class of drugs, which work by intercalating DNA strands and inhibiting the enzyme topoisomerase II. This action prevents the replication of cancer cells, leading to their death. Doxorubicin is typically administered intravenously and is known for its distinctive red color, earning it the nickname "Red Devil" due to its potent effects and significant side effect profile. Despite its efficacy, the use of doxorubicin is limited by its cardiotoxicity, which can lead to irreversible heart damage if not carefully monitored and managed.

The formulation and delivery methods of doxorubicin have seen significant advancements aimed at enhancing its therapeutic index and reducing its toxic side effects. One of the major breakthroughs in this area is the development of liposomal doxorubicin, which encapsulates the drug in liposomes, allowing for more targeted delivery to tumor cells while sparing healthy tissues. This modification has been shown to reduce cardiotoxicity and other systemic side effects, making treatment more tolerable for patients. Additionally, ongoing research is exploring the use of nanoparticles and other novel drug delivery systems to further improve the specificity and efficacy of doxorubicin. Advances in precision medicine are also paving the way for personalized dosing regimens based on individual patient profiles, aiming to maximize therapeutic outcomes while minimizing adverse effects.

The growth in the doxorubicin market is driven by several factors. The increasing incidence of cancer globally is a significant driver, as more patients require effective chemotherapeutic options. Advances in drug delivery technologies, such as liposomal formulations and nanoparticles, are enhancing the efficacy and safety profile of doxorubicin, encouraging its wider adoption. Furthermore, the expanding field of precision medicine is supporting the development of more tailored treatment regimens, potentially increasing the use of doxorubicin in combination therapies. Pharmaceutical companies are also investing heavily in research and development to explore new indications and combination treatments involving doxorubicin. Additionally, improvements in healthcare infrastructure and increased access to cancer treatment in emerging markets are boosting the demand for effective chemotherapy agents. These factors collectively underscore the dynamic and evolving nature of the doxorubicin market, driven by technological advancements, rising cancer prevalence, and ongoing research efforts.

Select Competitors (Total 59 Featured) -

  • Merck KGaA
  • Glenmark Pharmaceuticals Ltd.
  • Fresenius Kabi AG
  • Fresenius SE & Co. KGaA
  • Natco Pharma Limited
  • Meiji Holdings Co., Ltd.
  • Celsion Corporation
  • Health Biotech Ltd.
  • MicroBiopharm Japan Co., Ltd.
  • Accord Healthcare Ltd.
  • Olon S.p.A.
  • Seqens SAS
  • Biovencer Healthcare Private Limited
  • Avacta Group
  • CSPC Pharmaceutical Group Limited

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Doxorubicin - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Cancer - An Insight
    • Cancer Treatment
    • Chemotherapy: An Overview
    • An Introduction to Doxorubicin
  • GLOBAL MARKET OVERVIEW
    • Global Doxorubicin Market Set to Witness Rapid Growth
    • US Dominates the Doxorubicin Market, Asia-Pacific to Witness Fastest Growth
    • Breast Cancer Constitutes the Largest Application for Doxorubicin
    • Competition
    • New Entrants Seek Opportunities
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rise in Cancer Incidence to Drive Market Growth
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Liposomal Delivery Systems Offer Significant Benefits
    • A Review of Liposomal-Doxorubicin Preparations
    • DOX Hydrochloride
    • Ageing Demographics to Drive Demand
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Market to Gain from Rise in Number of Breast Cancer Cases
    • Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Doxorubicin
    • Age-Standardized Lung Cancer Rates for Select Countries
    • Lymphoma, Leukemia, Bladder Cancer, & Kaposi Sarcoma: Other Major Growth Areas
    • Uptrend in Healthcare Spending Drives the Doxorubicin Demand
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
    • Cancer Research Spending Continues to Witness Growth
    • A Netherlands Based Research Team Suggests a Variant of Doxorubicin can be Made more Effective without the Heart Damage Side Effect
    • Researchers Develop Non-Toxic and Precise Nanoscale Technology for Oncology Drug Delivery
    • Studies Show Positive Effect of Quantum Dot Enabled Doxorubicin Delivery in Lung Cancer Treatment
    • Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
    • Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Doxorucibin
    • Combination Therapy: A Double Whammy Success
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Doxorubicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Doxorubicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Ovarian Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Multiple Myeloma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Liver Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Kaposi Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Kaposi Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Kaposi Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Doxorubicin Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • MARKET ANALYSIS
    • Rising Cancer Cases Spur Growth in Doxorubicin Market
    • Personalized Medicine Gathers Momentum for Cancer Treatment in the US
    • TABLE 29: USA Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • MARKET ANALYSIS
    • Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Doxorubicin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Doxorubicin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • FRANCE
    • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 47: France Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: France Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: France 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 50: Germany Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Germany Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Germany 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 53: Italy Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Italy Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Italy 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 56: UK Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: UK Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: UK 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 59: Spain Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Spain Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Spain 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 62: Russia Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Russia Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Russia 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 65: Rest of Europe Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Rest of Europe Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Rest of Europe 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • MARKET ANALYSIS
    • An Insight into Asia-Pacific Market for Doxorubicin
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Doxorubicin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific Historic Review for Doxorubicin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Asia-Pacific 16-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 71: Asia-Pacific Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Asia-Pacific Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Asia-Pacific 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 74: Australia Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Australia Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Australia 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • INDIA
    • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 77: India Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: India Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: India 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 80: South Korea Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: South Korea Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: South Korea 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 83: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Asia-Pacific Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Asia-Pacific 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 86: Latin America Recent Past, Current & Future Analysis for Doxorubicin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 87: Latin America Historic Review for Doxorubicin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Latin America 16-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 89: Latin America Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Latin America Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Latin America 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 92: Argentina Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Argentina Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Argentina 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 95: Brazil Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Brazil Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Brazil 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 98: Mexico Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Mexico Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Mexico 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 101: Rest of Latin America Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Latin America Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Latin America 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 104: Middle East Recent Past, Current & Future Analysis for Doxorubicin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 105: Middle East Historic Review for Doxorubicin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Middle East 16-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 107: Middle East Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Middle East Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Middle East 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 110: Iran Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Iran Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Iran 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 113: Israel Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Israel Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Israel 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 116: Saudi Arabia Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Saudi Arabia Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Saudi Arabia 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 119: UAE Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UAE Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: UAE 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 122: Rest of Middle East Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Middle East Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Middle East 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
  • AFRICA
    • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 125: Africa Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Africa Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Africa 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION